Literature DB >> 17917866

The Test of Variables of Attention (TOVA): internal consistency (Q₁ vs. Q₂ and Q₃ vs. Q₄) in children with attention deficit/hyperactivity disorder (ADHD).

Antolin M Llorente1, Robert Voigt, Craig L Jensen, J Kennard Fraley, William C Heird, Kimberly M Rennie.   

Abstract

The internal consistency of the Test of Variables of Attention (TOVA) was examined in a cohort of 6- to 12-year-old children (N = 63) strictly diagnosed with ADHD. The internal consistency of errors of omission (OMM), errors of commission (COM), response time (RT), and response time variability (RTV) of different test conditions (stimulus infrequent condition [Q₁ vs. Q₂] and stimulus frequent condition [Q₃ vs. Q₄]) was assessed via correlation analyses. All TOVA index scores under investigation assessing its internal consistency exhibited statistically significant correlations. All correlations fell in the moderate-high range.

Entities:  

Mesh:

Year:  2007        PMID: 17917866     DOI: 10.1080/09297040701563578

Source DB:  PubMed          Journal:  Child Neuropsychol        ISSN: 0929-7049            Impact factor:   2.500


  7 in total

1.  Digital cognitive training in children with attention-deficit/hyperactivity disorder: a study protocol of a randomised controlled trial.

Authors:  Sally Richmond; Hannah Kirk; Tori Gaunson; Meg Bennett; Mark A Bellgrove; Kim Cornish
Journal:  BMJ Open       Date:  2022-06-16       Impact factor: 3.006

2.  Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia.

Authors:  Eric R Braverman; Amanda Lih-Chuan Chen; Thomas J H Chen; John D Schoolfield; Alison Notaro; Dasha Braverman; Mallory Kerner; Seth H Blum; Vanessa Arcuri; Michael Varshavskiy; Uma Damle; B William Downs; Roger L Waite; Marlene Oscar-Berman; John Giordano; Kenneth Blum
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-15       Impact factor: 2.570

3.  Omega-3 and Omega-6 Polyunsaturated Fatty Acid Levels and Correlations with Symptoms in Children with Attention Deficit Hyperactivity Disorder, Autistic Spectrum Disorder and Typically Developing Controls.

Authors:  Natalie Parletta; Theophile Niyonsenga; Jacques Duff
Journal:  PLoS One       Date:  2016-05-27       Impact factor: 3.240

4.  Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial.

Authors:  James D Kean; Jerome Sarris; Andrew Scholey; Richard Silberstein; Luke A Downey; Con Stough
Journal:  Psychopharmacology (Berl)       Date:  2016-12-05       Impact factor: 4.530

5.  A randomized controlled trial investigating the effects of PCSO-524, a patented oil extract of the New Zealand green lipped mussel (Perna canaliculus), on the behaviour, mood, cognition and neurophysiology of children and adolescents (aged 6-14 years) experiencing clinical and sub-clinical levels of hyperactivity and inattention: study protocol ACTRN12610000978066.

Authors:  James D Kean; David Camfield; Jerome Sarris; Marni Kras; Richard Silberstein; Andrew Scholey; Con Stough
Journal:  Nutr J       Date:  2013-07-16       Impact factor: 3.271

6.  A Randomized Controlled Trial Investigating the Effects of a Special Extract of Bacopa monnieri (CDRI 08) on Hyperactivity and Inattention in Male Children and Adolescents: BACHI Study Protocol (ANZCTRN12612000827831).

Authors:  James D Kean; Jordy Kaufman; Justine Lomas; Antionette Goh; David White; David Simpson; Andrew Scholey; Hemant Singh; Jerome Sarris; Andrea Zangara; Con Stough
Journal:  Nutrients       Date:  2015-12-02       Impact factor: 5.717

7.  Effects of schooling on aspects of attention in rural Burkina Faso, West Africa.

Authors:  Anselme Simeon Sanou; Abdoulaye Hama Diallo; Penny Holding; Victoria Nankabirwa; Ingunn Marie S Engebretsen; Grace Ndeezi; James K Tumwine; Nicolas Meda; Thorkild Tylleskar; Esperance Kashala-Abotnes
Journal:  PLoS One       Date:  2018-09-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.